{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T08:28:48Z","timestamp":1768724928652,"version":"3.49.0"},"reference-count":32,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multiple Myeloma (MM) often present with unspecific symptoms, which can lead to diagnostic delay. Serum-free light chain (sFLC) ratio is suggested to replace urine protein electrophoresis (UPE) in the diagnostic work-up of myeloma. We aimed to investigate the performance of the sFLC-ratio in general practice (GP) compared to UPE, just as we explored different sFLC-ratio cut-offs\u2019 influence on diagnostic values. In a cohort of 13,210 patients from GP measures of sFLC-ratio, serum protein electrophoresis (SPE), or UPE were compared to diagnoses of incident M-component related diseases acquired from Danish health registers. UPE and sFLC-ratio equally improved diagnostic values when combined with SPE (sensitivity: SPE and UPE: 95.6 (90.6\u201398.4); SPE and sFLC-ratio: 95.1 (90.2\u201398.0)). The addition of the sFLC-ratio to SPE resulted in the identification of 13 patients with MGUS, light chain disease and amyloidosis, which was in line with the addition of UPE to SPE. The number of false-positive tests was UPE and SPE: 364 (11%) and sFLC-ratio and SPE: 677(19%). Expanding sFLC-ratio reference range to 0.26\u20134.32 resulted in a significant reduction in false positives n = 226 (6%) without loss of patients with clinical plasma cell dyscrasias. sFLC-ratio improves the diagnostic value of SPE in GP. However, due to low specificity and a large number of false positives, expanded cut-off values should be considered.<\/jats:p>","DOI":"10.3390\/cancers14122930","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T23:50:14Z","timestamp":1655250614000},"page":"2930","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Cohort Study of Free Light Chain Ratio in Combination with Serum Protein Electrophoresis as a First-Line Test in General Practice"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-9165","authenticated-orcid":false,"given":"Birgitte","family":"Sandfeld-Paulsen","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6859-5296","authenticated-orcid":false,"given":"Ninna","family":"Aggerholm-Pedersen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark"},{"name":"Department of Experimental Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mie Hessellund","family":"Samson","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger Jon","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ingeman, M.L., Christensen, M.B., Bro, F., Knudsen, S.T., and Vedsted, P. (2015). The Danish cancer pathway for patients with serious non-specific symptoms and signs of cancer\u2014A cross-sectional study of patient characteristics and cancer probability. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1424-5"},{"key":"ref_2","unstructured":"Danckert, B., Ferlay, J., Engholm, G., Hansen, H.L., Johannesen, T.B., Khan, S., K\u00f8tlum, J.E., \u00d3lafsd\u00f3ttir, E., Schmidt, L.K.H., and Virtanen, A. (2020, October 08). NORDCAN: Cancer Incidence, Mortality, Prevalende and Survival in the Nordic Countries, Version 8.2 (26 March 2019). Available online: https:\/\/www-dep.iarc.fr\/NORDCAN\/DK\/frame.asp."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1373\/clinchem.2006.069104","article-title":"Serum free light chains: An alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies","volume":"52","author":"Hill","year":"2006","journal-title":"Clin. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1515\/CCLM.2011.010","article-title":"Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies","volume":"49","author":"Holding","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1309\/AJCP25IHYLEWCAHJ","article-title":"Replacing urine protein electrophoresis with serum free light chain analysis as a first-line test for detecting plasma cell disorders offers increased diagnostic accuracy and potential health benefit to patients","volume":"140","author":"McTaggart","year":"2013","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1182\/blood.V97.9.2900","article-title":"Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma","volume":"97","author":"Drayson","year":"2001","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2003.04433.x","article-title":"Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free im-munoglobulin light chains following chemotherapy","volume":"122","author":"Lachmann","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1309\/LYWM47K2L8XYFFB3","article-title":"Quantitative analysis of serum free light chains: A new marker for the diagnostic evaluation of primary systemic amyloidosis","volume":"119","author":"Gertz","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfh749","article-title":"Diagnosis and monitoring a case of light-chain deposition disease in the kidney using a new, sensitive immunoassay","volume":"20","author":"Brockhurst","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1309\/XE3UDARKW1B9EMWM","article-title":"Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins","volume":"124","author":"Bakshi","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_15","first-page":"157","article-title":"Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population","volume":"36","author":"Abadie","year":"2006","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1373\/clinchem.2008.106153","article-title":"Quantitation of serum free light chains in combination with protein electrophoresis and clinical infor-mation for diagnosing multiple myeloma in a general hospital population","volume":"54","author":"Piehler","year":"2008","journal-title":"Clin. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2141.2008.07369.x","article-title":"Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder","volume":"143","author":"Vermeersch","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(03)12457-9","article-title":"Serum test for assessment of patients with Bence Jones myeloma","volume":"361","author":"Bradwell","year":"2003","journal-title":"Lancet"},{"key":"ref_19","first-page":"12","article-title":"Primary care. Participants or gatekeepers?","volume":"17","author":"Starfield","year":"1994","journal-title":"Diabetes Care"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Jensen, H., T\u00f8rring, M.L., Olesen, F., Overgaard, J., and Vedsted, P. (2014). Cancer suspicion in general practice, urgent referral and time to diagnosis: A population-based GP survey and registry study. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-636"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"h5527","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: An updated list of essential items for reporting diagnostic accuracy studies","volume":"351","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","author":"Hutchison","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2369-9-11","article-title":"Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure","volume":"9","author":"Hutchison","year":"2008","journal-title":"BMC Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.50.0892","article-title":"Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis","volume":"32","author":"Weiss","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.3324\/haematol.2019.224360","article-title":"Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels","volume":"105","author":"Heaney","year":"2020","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: Recommendations from the European Myeloma Network","volume":"99","author":"Palumbo","year":"2014","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur. J. Epidemiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/ard.2006.052159","article-title":"Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren\u2019s syndrome","volume":"66","author":"Gottenberg","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1038\/bjc.2014.121","article-title":"Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma","volume":"110","author":"Teng","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s10067-018-4064-8","article-title":"Monoclonal gammopathy in rheumatic diseases","volume":"37","author":"Yang","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0004563215620441","article-title":"Validation of serum free light chain reference ranges in primary care","volume":"53","author":"Galvani","year":"2016","journal-title":"Ann. Clin. Biochem. Int. J. Lab. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/12\/2930\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:31:11Z","timestamp":1760139071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/12\/2930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14122930"],"URL":"https:\/\/doi.org\/10.3390\/cancers14122930","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]}}}